Free Trial
NASDAQ:QLGN

Qualigen Therapeutics 7/2/2024 Earnings Report

Qualigen Therapeutics logo
$3.76 +0.12 (+3.15%)
As of 03:30 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Qualigen Therapeutics EPS Results

Actual EPS
-$17.50
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Qualigen Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Qualigen Therapeutics Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Qualigen Therapeutics' next earnings date is estimated for Thursday, May 29, 2025, based on past reporting schedules.

Conference Call Resources

Qualigen Therapeutics Earnings Headlines

Elon’s 2025 Silver Crisis (What It Means for You)
Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless production of electric vehicles and solar technology is driving demand for the precious metal to unprecedented levels. Silver—critical for EV batteries, solar panels, and advanced electronics—is now at the center of a supply crisis.
See More Qualigen Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Qualigen Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Qualigen Therapeutics and other key companies, straight to your email.

About Qualigen Therapeutics

Qualigen Therapeutics (NASDAQ:QLGN), a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.

View Qualigen Therapeutics Profile

More Earnings Resources from MarketBeat